Neurizon and Clever Culture lead healthcare shares as trial funding and device orders lift sentiment

• Neurizon rose 35.71% after securing NIH support for wider NUZ-001 access and appointing a new chief executive.
• Clever Culture Systems gained 35.71% after Novo Nordisk ordered two more APAS Independence instruments.
• CONNEQT rose 23.53% for the week, but its price fell 4.55% after reopening at A$0.022.
• Cleo Diagnostics fell 18.18% despite appointing Asuragen to run a 1,470-sample ovarian cancer test study.